« Back
Home /
Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein (MHC-HM438)

Human HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein (MHC-HM438)

Item no.	MHC-HM438-500UG
Manufacturer	KactusBio
Amount	500 ug
Quantity options	100 ug 500 ug
Category	Oncology By Cell Type Blastoma Carcinoma Glioma Hematology Leukemia Lymphoma Myeloma Melanoma Sarcoma Peptides & Proteins Recombinant Proteins Cell Biology Adenocarcinoma Cytoskeleton By Organ Lung Cancer Colorectal Cancer Heart & Blood Cancer small GTPases Ras Subfamily
Type	Proteins Recombinant
Format	Lyophilized
Specific against	Human (Homo sapiens)
Host	HEK293
Conjugate/Tag	HIS, Avi
Purity	> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Formula	Supplied as 0.22μm filtered solution in PBS (pH 7.4).
Sequence	Gly25-Thr305(HLA-C*03:04), Ile21-Met119(B2M) and GADGVGKSAL peptide
NCBI	GADGVGKSAL
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	MHC,KRAS,K-Ras 2,KRAS2,C-K-RAS,CFC2,K-RAS2A,K-RAS2B,K-RAS4A,K-RAS4B,KRAS1,KRAS2,NS,NS3,RASK2,GTPase Kras,KI-RAS,RALD
Shipping Condition	Room temperature
Available
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL)
Manufacturer - Conjugate / Tag	C-His-Avi
Shipping Temperature	Shipped at ambient temperature.
Storage Conditions	-20 to -80°C for 12 months as supplied from date of receipt.；-80°C for 3 months after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Molecular Weight	The protein has a predicted MW of 50.30 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Description	Recombinant Human HLA-C03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Gly25-Thr305(HLA-C03:04), Ile21-Met119(B2M) and GADGVGKSAL peptide.
Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500μg or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Biotinylated	no

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

MHC-HM438-500UG-datasheet.pdf

MHC-HM438-500UG-safety-datasheet.pdf